AstraZeneca Pharmaceuticals LP
950 Wind River Lane
About AstraZeneca Pharmaceuticals LP
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
CEO: Pascal Soriot
CFO: Marc Dunoyer
CMO: Marc Dunoyer
CTO: Andrew Chen
CCO: Katarina Ageborg
CMO: Sean Bohen
Please click here for clinical trial information.
Please click here for AstraZeneca job opportunities.
For more information, visit
www.astrazeneca.com and follow us on www.twitter.com/astrazeneca.
Tweets by AstraZeneca
What Science Can Do
1832 articles with AstraZeneca Pharmaceuticals LP
The U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Imfinzi to treat patients with unresectable Stage III non-small cell lung cancer (NSCLC).
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed IONIS-AZ5-2.5 Rx (AZD2373) to the global, science-led biopharmaceutical company AstraZeneca (NYSE: AZN).
2/17/2018IMFINZI is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer.
AstraZeneca and Merck announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
The first patient has been dosed in an expansion cohort in the Phase 1b segment of the Phase 1 study in advanced solid tumours.
Failing numbers are putting a strain on CEO Pascal Soriot's pledge of achieving $45B of annual revenue by 2023.
AstraZeneca did not immediately respond to a request for comment.
Under the terms of the agreement, Syndax and Astra will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in multiple solid tumor types.
Astra has Glaxo and its COPD treatment Trelegy Ellipta squarely in its sights.
TissUse continues their successfulcollaboration with Astra to establish relevant MPS models based on TissUse's Multi-Organ-Chip technology.
Astra has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reuters reported Thursday.
The survey of 51 oncologists suggests broad uptake of Imfinzi in advanced lung cancer patients who can't be treated with surgery.
Astrazeneca Release: LYNPARZA (olaparib) Receives Approval in Japan for the Treatment of Advanced Ovarian Cancer
AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Japanese Ministry of Health, Labour and Welfare has approved LYNPARZA® (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy.
The new agreement focuses on the synthesis and delivery of custom libraries to AstraZeneca as well as the transfer of the DEX platform, allowing for in-house screening of DNA-encoded libraries at AstraZeneca.
1/17/2018Despite some safety concerns such as severe diarrhea, the FDA approved Puma's breast cancer drug Nerlynx in July 2017.
Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility
The companies held an opening ceremony to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate.
Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer.
AstraZeneca's BYDUREON BCise Injectable Medicine Now Available in the U.S. for Patients With Type-2 Diabetes
BYDUREON BCise is a new formulation of BYDUREON injectable suspension 2mg in an improved once-weekly, single-dose autoinjector device.
Financial terms of the deal were not disclosed.
ANI Phamaceuticals funded the acquisitions through a combination of cash and debt.